Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.
Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Abd-Elsalam S, et al. Among authors: soliman s. Arch Virol. 2018 Jan;163(1):51-56. doi: 10.1007/s00705-017-3573-0. Epub 2017 Oct 5. Arch Virol. 2018. Retraction in: Arch Virol. 2022 Nov;167(11):2441. doi: 10.1007/s00705-022-05600-w PMID: 28983675 Retracted.
Genetic Susceptibility in Family Members of Egyptian Hepatitis C Virus Infected Patients: Role of Interleukin-12 B Gene Polymorphism.
Elwan N, Assal F, Elfert A, AboAli L, Soliman S, Soliman S, Elkhalawany W, Badawy R, Effat L, Sayed K, Shalaby S, Shehab M, Abdel-Hamid M, Abd-Elsalam S. Elwan N, et al. Among authors: soliman s. Infect Disord Drug Targets. 2019;19(1):81-87. doi: 10.2174/1871526518666171227210541. Infect Disord Drug Targets. 2019. PMID: 29283074
Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.
Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, Esheba NE, Elnaggar MH, Soliman S, Abd-Elsalam S. Ahmed OA, et al. Among authors: soliman s. Infect Drug Resist. 2018 Mar 28;11:441-445. doi: 10.2147/IDR.S160593. eCollection 2018. Infect Drug Resist. 2018. PMID: 29628768 Free PMC article.
Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
Abd-Elsalam S, Badawi R, Elnawasany S, Yousef M, Mansour L, Hawash N, Elkhouly RA, Soliman S, Selim A, Kobtan A, Elfert A. Abd-Elsalam S, et al. Among authors: soliman s. Infect Disord Drug Targets. 2019;19(2):179-184. doi: 10.2174/1871526518666180912121835. Infect Disord Drug Targets. 2019. PMID: 30207250 Clinical Trial.
908 results